GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Inventories, Finished Goods

BeiGene (STU:49B) Inventories, Finished Goods : €221 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Inventories, Finished Goods?

BeiGene's quarterly finished goods increased from Sep. 2023 (€171 Mil) to Dec. 2023 (€209 Mil) and increased from Dec. 2023 (€209 Mil) to Mar. 2024 (€221 Mil).

BeiGene's annual finished goods increased from Dec. 2021 (€137 Mil) to Dec. 2022 (€163 Mil) and increased from Dec. 2022 (€163 Mil) to Dec. 2023 (€209 Mil).

BeiGene Inventories, Finished Goods Historical Data

The historical data trend for BeiGene's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Inventories, Finished Goods Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.70 56.38 137.25 162.84 209.31

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.95 166.89 171.35 209.31 221.03

BeiGene Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

BeiGene (STU:49B) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Inventories, Finished Goods
Comparable Companies
BNTX ALNY BMRN MRNA RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Website
https://www.beigene.com
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (STU:49B) Headlines

No Headlines